Study identifier:9238IL/0025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, randomized, multicentre trial comparing the efficacy and tolerability of 250mg of Faslodex (long acting ICI 182,780) with 20mg of Nolvadex (Tamoxifen) in postmenopausal women with advanced breast cancer
Breast Cancer
Phase 3
No
Fulvestrant, Tamoxifen
Female
51
Interventional
N/A
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.
Location
Location
Buenos Aires, Argentina
Location
Rosario, Argentina
Location
Camperdown, Australia
Location
Concord, Australia
Location
Heidelburg, Australia
Location
Melbourne, Australia
Location
Salzburg, Austria
Location
Wien, Austria
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Tamoxifen | Drug: Tamoxifen 20 mg oral tablet Other Name: Nolvadex |
Experimental: 2 Fulvestrant | Drug: Fulvestrant intramuscular injection 250 mg Other Name: Faslodex Other Name: ZD9238 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.